245 related articles for article (PubMed ID: 9579237)
21. A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma.
Diamond T; Nery L; Hales I
J Clin Endocrinol Metab; 1991 Jun; 72(6):1184-8. PubMed ID: 2026740
[TBL] [Abstract][Full Text] [Related]
22. Bone mineral density in pre-and post-menopausal women with affective disorder treated with long-term L-thyroxine augmentation.
Gyulai L; Bauer M; Garcia-Espana F; Hierholzer J; Baumgartner A; Berghöfer A; Whybrow PC
J Affect Disord; 2001 Oct; 66(2-3):185-91. PubMed ID: 11578671
[TBL] [Abstract][Full Text] [Related]
23. Thyroid hormone use and bone mineral density in elderly women. Effects of estrogen.
Schneider DL; Barrett-Connor EL; Morton DJ
JAMA; 1994 Apr; 271(16):1245-9. PubMed ID: 7848399
[TBL] [Abstract][Full Text] [Related]
24. The level of TSH appeared favourable in maintaining bone mineral density in postmenopausal women.
Baqi L; Payer J; Killinger Z; Susienkova K; Jackuliak P; Cierny D; Langer P
Endocr Regul; 2010 Jan; 44(1):9-15. PubMed ID: 20151763
[TBL] [Abstract][Full Text] [Related]
25. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine.
Marcocci C; Golia F; Vignali E; Pinchera A
J Bone Miner Res; 1997 Jan; 12(1):72-7. PubMed ID: 9240728
[TBL] [Abstract][Full Text] [Related]
26. Bone changes in pre- and postmenopausal women with thyroid cancer on levothyroxine therapy: evolution of axial and appendicular bone mass.
Jódar E; Begoña López M; García L; Rigopoulou D; Martínez G; Hawkins F
Osteoporos Int; 1998; 8(4):311-6. PubMed ID: 10024900
[TBL] [Abstract][Full Text] [Related]
27. Bone mineral density in patients receiving suppressive doses of thyroxine for thyroid carcinoma.
Florkowski CM; Brownlie BE; Elliot JR; Ayling EM; Turner JG
N Z Med J; 1993 Oct; 106(966):443-4. PubMed ID: 8233173
[TBL] [Abstract][Full Text] [Related]
28. Long-term change in the bone mineral density of adults with adult onset growth hormone (GH) deficiency in response to short or long-term GH replacement therapy.
Rahim A; Holmes SJ; Adams JE; Shalet SM
Clin Endocrinol (Oxf); 1998 Apr; 48(4):463-9. PubMed ID: 9640413
[TBL] [Abstract][Full Text] [Related]
29. Replacement therapy with levothyroxine plus triiodothyronine (bioavailable molar ratio 14 : 1) is not superior to thyroxine alone to improve well-being and cognitive performance in hypothyroidism.
Siegmund W; Spieker K; Weike AI; Giessmann T; Modess C; Dabers T; Kirsch G; Sänger E; Engel G; Hamm AO; Nauck M; Meng W
Clin Endocrinol (Oxf); 2004 Jun; 60(6):750-7. PubMed ID: 15163340
[TBL] [Abstract][Full Text] [Related]
30. Effect of long-term L-thyroxine treatment on bone mineral density in young adults with congenital hypothyroidism.
Salerno M; Lettiero T; Esposito-del Puente A; Esposito V; Capalbo D; Carpinelli A; Padula S; del Puente A
Eur J Endocrinol; 2004 Dec; 151(6):689-94. PubMed ID: 15588234
[TBL] [Abstract][Full Text] [Related]
31. Determination of bone mineral density by quantitative computed tomography and single photon absorptiometry in subclinical hyperthyroidism: a risk of early osteopaenia in post-menopausal women.
Lehmke J; Bogner U; Felsenberg D; Peters H; Schleusener H
Clin Endocrinol (Oxf); 1992 May; 36(5):511-7. PubMed ID: 1617803
[TBL] [Abstract][Full Text] [Related]
32. Global skeletal uptake of technetium-99m methylene diphosphonate in female patients receiving suppressive doses of L-thyroxine for differentiated thyroid cancer.
Frusciante V; Carnevale V; Scillitani A; Zingrillo M; Dicembrino F; Giannatempo GM; Ghiggi MR; Minisola S
Eur J Nucl Med; 1998 Feb; 25(2):139-43. PubMed ID: 9473261
[TBL] [Abstract][Full Text] [Related]
33. Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women.
Faber J; Jensen IW; Petersen L; Nygaard B; Hegedüs L; Siersbaek-Nielsen K
Clin Endocrinol (Oxf); 1998 Mar; 48(3):285-90. PubMed ID: 9578817
[TBL] [Abstract][Full Text] [Related]
34. Thyroxine replacement therapy and circulating lipid concentrations.
Franklyn JA; Daykin J; Betteridge J; Hughes EA; Holder R; Jones SR; Sheppard MC
Clin Endocrinol (Oxf); 1993 May; 38(5):453-9. PubMed ID: 8330440
[TBL] [Abstract][Full Text] [Related]
35. Bone mass after long-term euthyroidism in former hyperthyroid women treated with (131)I influence of menopausal status.
Serraclara A; Jódar E; Sarabia F; Hawkins F
J Clin Densitom; 2001; 4(3):249-55. PubMed ID: 11740067
[TBL] [Abstract][Full Text] [Related]
36. The effect of life-long thyroxine treatment and physical activity on bone mineral density in young adult women with congenital hypothyroidism.
Kempers MJ; Vulsma T; Wiedijk BM; de Vijlder JJ; van Eck-Smit BL; Verberne HJ
J Pediatr Endocrinol Metab; 2006 Dec; 19(12):1405-12. PubMed ID: 17252693
[TBL] [Abstract][Full Text] [Related]
37. Bone mineral density in adolescent females treated with L-thyroxine: a longitudinal study.
Saggese G; Bertelloni S; Baroncelli GI; Costa S; Ceccarelli C
Eur J Pediatr; 1996 Jun; 155(6):452-7. PubMed ID: 8789760
[TBL] [Abstract][Full Text] [Related]
38. Interfemur variation of bone mineral density in patients receiving high-dose thyroxin therapy.
Goerres G; Theiler R; Müller-Brand J
Calcif Tissue Int; 1998 Aug; 63(2):98-101. PubMed ID: 9685511
[TBL] [Abstract][Full Text] [Related]
39. High-normal free thyroxine levels are associated with low trabecular bone scores in euthyroid postmenopausal women.
Hwangbo Y; Kim JH; Kim SW; Park YJ; Park DJ; Kim SY; Shin CS; Cho NH
Osteoporos Int; 2016 Feb; 27(2):457-62. PubMed ID: 26252978
[TBL] [Abstract][Full Text] [Related]
40. Bone mineral density and metabolism in children with congenital hypothyroidism after prolonged L-thyroxine therapy.
Leger J; Ruiz JC; Guibourdenche J; Kindermans C; Garabedian M; Czernichow P
Acta Paediatr; 1997 Jul; 86(7):704-10. PubMed ID: 9240877
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
